ScholarIQanswers from OpenAlex & ORCID
David Fitchett
ResearcherPublications, citations & collaboration network
David Fitchett is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does David Fitchett have?
ScholarIQindexed works
David Fitchett has 324 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does David Fitchett have?
ScholarIQcitation count
David Fitchett has 29,304 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of David Fitchett?
ScholarIQh-index
David Fitchett has an h-index of 60 in OpenAlex.
What is the i10-index of David Fitchett?
ScholarIQi10-index
David Fitchett has an i10-index of 142 in OpenAlex.
What is the ORCID of David Fitchett?
ScholarIQorcid
The ORCID for David Fitchett is on the source record.
What is the OpenAlex record for David Fitchett?
ScholarIQopenalex
The OpenAlex for David Fitchett is on the source record.
What are the most-cited papers on David Fitchett?
ScholarIQmost cited works
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman, Christoph Wanner, John M. Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J. Woerle, Uli C. Broedl, Silvio E. Inzucchi
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner, Silvio E. Inzucchi, John M. Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J. Woerle, Uli C. Broedl, Bernard Zinman
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus
Hiddo J.L. Heerspink, Bruce A. Perkins, David Fitchett, Mansoor Husain, David Z.I. Cherney
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME <sup>®</sup> trial
David Fitchett, Bernard Zinman, Christoph Wanner, John M. Lachin, Stefan Hantel, Afshin Salsali, Odd Erik Johansen, Hans J. Woerle, Uli C. Broedl, Silvio E. Inzucchi
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial
Silvio E. Inzucchi, Bernard Zinman, David Fitchett, Christoph Wanner, Ele Ferrannini, Martin Schumacher, Claudia Schmoor, Kristin Ohneberg, Odd Erik Johansen, Jyothis T. George, Stefan Hantel, Erich Bluhmki, John M. Lachin